Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Short term Debt (2016 - 2022)

Lexaria Bioscience's Short term Debt history spans 8 years, with the latest figure at $7906.0 for Q2 2022.

  • Quarterly results put Short term Debt at $7906.0 for Q2 2022, up 5.32% from a year ago — trailing twelve months through May 2022 was $7906.0 (up 5.32% YoY), and the annual figure for FY2021 was $7926.0, down 86.5%.
  • Short term Debt for Q2 2022 was $7906.0 at Lexaria Bioscience, roughly flat from $7875.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $206806.0 in Q1 2021 to a low of $1600.0 in Q1 2020.
  • The 5-year median for Short term Debt is $8518.0 (2018), against an average of $32169.2.
  • The sharpest move saw Short term Debt plummeted 98.02% in 2018, then surged 12825.38% in 2021.
  • Year by year, Short term Debt stood at $21654.0 in 2018, then skyrocketed by 71.79% to $37200.0 in 2019, then soared by 134.37% to $87185.0 in 2020, then crashed by 91.03% to $7817.0 in 2021, then increased by 1.14% to $7906.0 in 2022.
  • According to Business Quant data, Short term Debt over the past three periods came in at $7906.0, $7875.0, and $7817.0 for Q2 2022, Q1 2022, and Q4 2021 respectively.